Literature DB >> 12205233

Occupational exposure to cytotoxic drugs in two UK oncology wards.

E Ziegler1, Howard J Mason, P J Baxter.   

Abstract

AIMS: To investigate the potential exposure to cytotoxic drugs of staff on two oncology wards in a large district, UK hospital under normal working conditions.
METHODS: Cytotoxic drug exposure was monitored in urine samples, surface wipes, and on disposable gloves by using a number of commonly used marker drugs, namely cyclophosphamide, ifosfamide, methotrexate, and the platino coordinated drugs. Questionnaire data on their work practices, potential exposure, use of protective personal equipment, and relevant training were collected from nursing, domestic, and clerical staff on two oncology wards.
RESULTS: The majority of staff were female with a mean age of 31 years. Roughly half of the staff studied were specifically trained nurses with an average of 3.5 years experience of administering cytotoxic drugs. No cytotoxic drug preparation or reconstitution was carried out on the wards. Disposable gloves, plastic armlets and aprons, but not eye protection, were invariably worn where there was potential exposure to cytotoxics. No cytotoxic drug was detected in any of the staff's urine samples. Isolated disposable latex gloves from nurses administering drugs showed some contamination, as did some surfaces within the wards' sluice rooms, but not in the ward areas where the drugs were stored and checked prior to administration.
CONCLUSIONS: The risk management strategies in place, including use of personal protective equipment, staff training, and other organisational measures, have ensured that internal exposure is lower than the detection limits for the current biological monitoring methods. Levels of contamination appear significantly lower than earlier, non-UK published studies where different risk management strategies were in place and, in particular, ward staff may have been involved in some degree of cytotoxic drug reconstitution.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205233      PMCID: PMC1740366          DOI: 10.1136/oem.59.9.608

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  29 in total

1.  Capability of ICP-MS (pneumatic nebulization and ETV) for Pt-analysis in different matrices at ecologically relevant concentrations.

Authors:  P Schramel; I Wendler; S Lustig
Journal:  Anal Bioanal Chem       Date:  1995-09       Impact factor: 4.142

2.  Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists.

Authors:  B Valanis; W M Vollmer; P Steele
Journal:  J Occup Environ Med       Date:  1999-08       Impact factor: 2.162

3.  Cytogenetic consequences after occupational exposure to antineoplastic drugs.

Authors:  A Fucic; A Jazbec; A Mijic; D Seso-Simic; R Tomek
Journal:  Mutat Res       Date:  1998-08-07       Impact factor: 2.433

4.  Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide.

Authors:  C T Evelo; R P Bos; J G Peters; P T Henderson
Journal:  Int Arch Occup Environ Health       Date:  1986       Impact factor: 3.015

5.  Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs.

Authors:  A S Ensslin; Y Stoll; A Pethran; A Pfaller; H Römmelt; G Fruhmann
Journal:  Occup Environ Med       Date:  1994-04       Impact factor: 4.402

6.  Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs.

Authors:  A S Ensslin; A Pethran; R Schierl; G Fruhmann
Journal:  Int Arch Occup Environ Health       Date:  1994       Impact factor: 3.015

7.  The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.

Authors:  P Seideman; O Beck; S Eksborg; M Wennberg
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

8.  Leukaemia and reproductive outcome among nurses handling antineoplastic drugs.

Authors:  T Skov; B Maarup; J Olsen; M Rørth; H Winthereik; E Lynge
Journal:  Br J Ind Med       Date:  1992-12

9.  Long-term platinum excretion in patients treated with cisplatin.

Authors:  R Schierl; B Rohrer; J Hohnloser
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Exposure of hospital pharmacists and nurses to antineoplastic agents.

Authors:  J J McDevitt; P S Lees; M A McDiarmid
Journal:  J Occup Med       Date:  1993-01
View more
  11 in total

1.  Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach.

Authors:  Massimo Moretti; Maria Giuseppa Grollino; Sofia Pavanello; Roberta Bonfiglioli; Milena Villarini; Massimo Appolloni; Mariella Carrieri; Laura Sabatini; Luca Dominici; Laura Stronati; Giuseppe Mastrangelo; Anna Barbieri; Cristina Fatigoni; Giovanni Battista Bartolucci; Elisabetta Ceretti; Francesca Mussi; Silvano Monarca
Journal:  Int Arch Occup Environ Health       Date:  2014-11-02       Impact factor: 3.015

2.  Occupational exposure to chemotherapy of pharmacy personnel at a single centre.

Authors:  Raveena Ramphal; Tejinder Bains; Geneviève Goulet; Régis Vaillancourt
Journal:  Can J Hosp Pharm       Date:  2015 Mar-Apr

3.  Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs.

Authors:  Cinzia Lucia Ursini; Delia Cavallo; Antonio Colombi; Margherita Giglio; Alessandro Marinaccio; Sergio Iavicoli
Journal:  Int Arch Occup Environ Health       Date:  2006-06-08       Impact factor: 3.015

4.  Occupational exposure of platinum-based anti-cancer drugs: five-year monitoring of hair and environmental samples in a single hospital.

Authors:  Ai Hori; Mari Shimura; Yutaka Iida; Kazuhiko Yamada; Kyoko Nohara; Takayuki Ichinose; Ai Yamashita; Junko Shirataki; Shotaro Hagiwara
Journal:  J Occup Med Toxicol       Date:  2020-09-29       Impact factor: 2.646

5.  Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital.

Authors:  M Hedmer; H Tinnerberg; A Axmon; B A G Jönsson
Journal:  Int Arch Occup Environ Health       Date:  2007-12-08       Impact factor: 3.015

6.  A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project.

Authors:  Massimo Moretti; Roberta Bonfiglioli; Donatella Feretti; Sofia Pavanello; Francesca Mussi; Maria G Grollino; Milena Villarini; Anna Barbieri; Elisabetta Ceretti; Mariella Carrieri; Annamaria Buschini; Massimo Appolloni; Luca Dominici; Laura Sabatini; Umberto Gelatti; Giovanni B Bartolucci; Paola Poli; Laura Stronati; Giuseppe Mastrangelo; Silvano Monarca
Journal:  BMC Public Health       Date:  2011-03-30       Impact factor: 3.295

7.  Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.

Authors:  E E M Brouwers; A D R Huitema; E N Bakker; J W Douma; K J M Schimmel; G van Weringh; P J de Wolf; J H M Schellens; J H Beijnen
Journal:  Int Arch Occup Environ Health       Date:  2007-03-22       Impact factor: 3.015

8.  Risks to health professionals from hazardous drugs in Iran: a pilot study of understanding of healthcare team to occupational exposure to cytotoxics.

Authors:  Abdol Ali Shahrasbi; Minoo Afshar; Farnaz Shokraneh; Faezeh Monji; Mahjabin Noroozi; Maryam Ebrahimi-Khojin; Seyed Farzam Madani; Mehdi Ahadi-Barzoki; Mehdi Rajabi
Journal:  EXCLI J       Date:  2014-05-09       Impact factor: 4.068

9.  Assessment of Nurse's Safe Behavior Towards Chemotherapy Management.

Authors:  Maria Koulounti; Zoe Roupa; Charalambos Charalambous; Maria Noula
Journal:  Mater Sociomed       Date:  2019-12

10.  Environmental Contamination and Occupational Exposure of Algerian Hospital Workers.

Authors:  Eline Verscheure; Matteo Creta; Jeroen Vanoirbeek; Meziane Zakia; Taleb Abdesselam; Robin Lebegge; Katrien Poels; Radu-Corneliu Duca; Lode Godderis
Journal:  Front Public Health       Date:  2020-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.